Prime Medicine Inc
NASDAQ:PRME
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sundaram Brake Linings Ltd
NSE:SUNDRMBRAK
|
IN |
Prime Medicine Inc
Common Stock
Prime Medicine Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Prime Medicine Inc
NASDAQ:PRME
|
Common Stock
$2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-85%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Common Stock
$18m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Common Stock
$1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Common Stock
$2.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Common Stock
$101.8k
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
Prime Medicine Inc
Glance View
Prime Medicine Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2022-10-20. Prime Medicine, Inc. is a United States-based biotechnology company. The firm is engaged in multiple drug discovery programs that target liver, eye, ex-vivo hematopoietic stem cell and neuro-muscular indications. The firm's Prime Editing, a transformative technology that addressed the cause of genetic disease. The firm's collaborative approach help fight disease and accelerating the development of Prime Editing to deliver therapies for patients. Its Prime Editing is used to modify gene-regulatory sequences. These edits can be made in therapeutically relevant cells and organs, including specialized terminally differentiated cells. Its Prime Editing acts as a Deoxyribonucleic acid (DNA) word processor, with the power to search and replace genetic sequences at their exact location in the genome, all without making double-strand breaks in DNA.
See Also
What is Prime Medicine Inc's Common Stock?
Common Stock
2k
USD
Based on the financial report for Dec 31, 2025, Prime Medicine Inc's Common Stock amounts to 2k USD.
What is Prime Medicine Inc's Common Stock growth rate?
Common Stock CAGR 5Y
-85%
Over the last year, the Common Stock growth was 0%.
